{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-232514","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2025-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.042206+00:00","generated_at":"2026-05-17T04:29:32.421019+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lexeo gets FDA feedback for LX2006 accelerated approval; interim data show LVMI reduction, mFARS improvement","bullets":["FDA open to pooling ongoing Phase 1/2 data with pivotal study to support BLA for accelerated approval.","Abnormal-LVMI patients (n=6): 18% mean reduction at 6 months, 23% at 12 months, exceeding 10% FDA threshold.","All participants (n=16) >6-mo follow-up: 2.0-point mean mFARS improvement; 11 of 16 improved or stabilized.","LX2006 generally well tolerated; no Grade 3+ SAEs; no discontinuations; one Grade 2 asymptomatic myocarditis.","Lexeo plans to initiate LX2006 pivotal study as soon as possible in first half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-232514","json":"https://secwatch.observer/filing/0001193125-25-232514.json","markdown":"https://secwatch.observer/filing/0001193125-25-232514.md","text":"https://secwatch.observer/filing/0001193125-25-232514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000119312525232514/0001193125-25-232514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000119312525232514/lxeo-20251007.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:29:32.421019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}